FDA approves fast-acting Viagra rival, Stendra

Share on Nextdoor

Clinical trials of Stendra showed that it started working in as little as 15 minutes, compared to an hour for Viagra.


While Stendra also works by increasing blood flow to the penis, the clinical trials suggest that Stendra is more selective. This specificity is expected to result in fewer side-effects.


With over 30 million men in the US suffering from some form of ED, it is anticipated that Stendra will pull in about $300 million in sales annually. In contrast, Viagra earned about $2 billion in 2011. Interestingly enough, a new erection medication may not be enough to arouse investors. Market analysts are more excited about the earning potential of Vivus's obesity drug, Qnexa, which will be reviewed by the FDA in July.


Read more at FoxNews.com


Follow Alfie on Twitter or Facebook and email him if interested in writing about Sex & Love

Avanafil, which will sell under the name, Stendra, just became the first new erectile dysfunction (ED) drug to be approved by the FDA in a decade.

Stendra's parent company, Vivus Inc., will compete with the three other ED medications on the US market: Viagra, Cialis, and Levitra. However, the new drug may have a leg up on the competition.

Scroll to read more Tampa Bay News articles

Newsletters

Join Creative Loafing Tampa Bay Newsletters

Subscribe now to get the latest news delivered right to your inbox.